Introduction: The use of proton-pump inhibitors (PPI) may be associated with an increased
risk of gastric cancer (GC). Objective: To review and meta-analyse available literature …

Objective Proton pump inhibitor (PPI) use has risen substantially, primarily driven by
ongoing use over months to years. However, there is no consensus on how to define long …

Angiogenesis contributes to the development of nonalcoholic steatohepatitis (NASH) and
promotes inflammation, fibrosis, and progression to hepatocellular carcinoma (HCC) …

Background The long-term safety of proton pump inhibitors (PPIs) is increasingly
questioned. The aim of our study was to assess the risk of pancreatic cancer among long …

Background Proton pump inhibitor (PPI) use has been reported to be associated with liver
damage and might possibly be carcinogenic. Aims We examined whether long‐term PPI use …

Proton pump inhibitors (PPIs) are used for the long-term treatment of gastroesophageal
disorders and the non-prescription medicines for acid reflux. However, there is growing …

Abstract Background Proton pump inhibitors (PPIs) may be associated with gastric cancer,
but studies in recent years have proven still inconsistent results. We conducted a systematic …

Researchers have hypothesized that the long‐term use of proton pump inhibitors (PPIs) can
increase the risk of developing cancer. However, the association between PPI use and …

Although current evidence suggests potential antitumor activity of proton pump inhibitors
(PPIs), there is no population‐based evidence of an association between PPI use and …

Cirrhotic cardiomyopathy (CCM), a comorbidity of end‐stage cirrhotic liver disease, remains
uncharacterized in children, largely because of a lack of an established pediatric definition …